Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Entolimod
product8 mentionslast seen Nov 2, 2026
Investigational biologic designed as a potential medical countermeasure for acute radiation syndrome.
Relationships 13
- Entolimodapplies toacute radiation syndrome treatment99% confidence8 sources
- Valion Bio, Inc.developsEntolimod99% confidence8 sources
- Entolimoddepends onToll-like Receptor 5 agonist99% confidence7 sources
- U.S. Food and Drug AdministrationapprovesEntolimod97% confidence2 sources
- Entolimodconforms toU.S. Food and Drug Administration97% confidence1 source
- Entolimodapplies togastrointestinal acute radiation syndrome treatment92% confidence1 source
- Statera BiopharmaownsEntolimod88% confidence1 source
- Entolimodconforms toFDA Animal Rule88% confidence1 source
- Entolimodcomposed ofBioViscid85% confidence1 source
- Valion Bio, Inc.commercializesEntolimod85% confidence1 source
- Armed Forces Radiobiology Research InstitutedevelopsEntolimod85% confidence1 source
- Entolimodapplies toradiation-induced neutropenia treatment82% confidence1 source
- Statera BiopharmadevelopsEntolimod80% confidence1 source
Relationship
Valion Bio, Inc.developsEntolimod
99% confidence8 supporting mentions
Either name opens that entity’s relationships.
Sources 8
- filingSEC EDGARNov 2, 2026Valion Bio, Inc. 8-K: Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ: VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics
- filingSEC EDGAROct 29, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ: VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today announced final data from a National Institute of Allergy and Infectious Diseases ("NIAID")/Radiation and Nuclear Countermeasures Program ("RNCP")-funded safety study of its lead biologic drug candidate, Entolimod
- filingSEC EDGAROct 26, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
its lead biologic drug candidate, Entolimod
- filingSEC EDGAROct 22, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod, Valion's lead biologic drug candidate for Acute Radiation Syndrome
- filingSEC EDGAROct 15, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
The Company's lead candidate, Entolimod, is being developed as a potential medical countermeasure for Acute Radiation Syndrome
- filingSEC EDGAROct 14, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today highlighted the capabilities of its wholly owned contract development and manufacturing organization ("CDMO"), Velocity Bioworks. Velocity Bioworks ("Velocity") is part of Valion's own domestic biologics supply chain, supporting the Company's development strategy for its lead candidate, Entolimod
- filingSEC EDGAROct 6, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Entolimod is an investigational Toll-like receptor 5 (TLR5) agonist being developed
- filingSEC EDGAROct 1, 2026Valion Bio, Inc. 8-K: Item 8.01: Other Events; Item 9.01: Financial Statements and Exhibits
Valion holds an exclusive worldwide license from Statera Biopharma to develop and commercialize Entolimod